Sanchez E et al. – The results suggest that INNO–206 may provide multiple myeloma (MM) patients with an anthracycline that may be administered safely at higher doses compared to free doxorubicin, resulting in superior efficacy compared to the currently available anthracyclines to treat this B cell malignancy. [more...]
Register now to view all the MDLinx contents (FREE)!
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close